SNDX May 2024 25.000 put
| Previous Close | 3.1600 |
| Open | 3.1600 |
| Bid | 2.1000 |
| Ask | 3.0000 |
| Strike | 25.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 3.1600 - 3.1600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 40 |
PR NewswireSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended March 31, 2024, and provided a business update.
PR NewswireSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on May 1, 2024 the Company granted inducement awards to purchase up to 100,600 shares of common stock to six new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying
PR NewswireSyndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 8, 2024.
